Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 17.23 -2.93% -0.52
ICPT closed down 2.93 percent on Thursday, May 13, 2021, on 63 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical ICPT trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
180 Bearish Setup Bearish Swing Setup -2.93%
Slingshot Bearish Bearish Swing Setup -2.93%
Lower Bollinger Band Walk Weakness -2.93%
Wide Bands Range Expansion -2.93%
Oversold Stochastic Weakness -2.93%
Slingshot Bearish Bearish Swing Setup -5.33%
Bullish Engulfing Bullish -5.33%
Lower Bollinger Band Walk Weakness -5.33%
New 52 Week Low Weakness -5.33%
Older End-of-Day Signals for ICPT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 16 hours ago
Down 2 % about 18 hours ago
60 Minute Opening Range Breakdown about 18 hours ago
Down 1% about 18 hours ago
Bearish 180 Entry about 18 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Intercept Pharmaceuticals, Inc. Description

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.


Sector: Healthcare
Industry: Biotechnology
Keywords: Acid Alcohol Diabetes Hypertension Gastroenterology Steatohepatitis Liver Disease Hepatology Diarrhea Fibrosis Liver Diseases Bile Acid Digestive Diseases Chronic Liver Disease Chronic Liver Diseases Cirrhosis Primary Biliary Cholangitis Farnesoid X Receptor Fxr Obeticholic Acid

Is ICPT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 94.5
52 Week Low 16.26
Average Volume 1,113,664
200-Day Moving Average 32.54
50-Day Moving Average 21.22
20-Day Moving Average 19.57
10-Day Moving Average 18.22
Average True Range 1.27
ADX 30.45
+DI 14.39
-DI 28.58
Chandelier Exit (Long, 3 ATRs ) 18.53
Chandelier Exit (Short, 3 ATRs ) 20.08
Upper Bollinger Band 22.75
Lower Bollinger Band 16.39
Percent B (%b) 0.13
BandWidth 32.50
MACD Line -1.34
MACD Signal Line -1.18
MACD Histogram -0.159
Fundamentals Value
Market Cap 568.46 Million
Num Shares 33 Million
EPS -10.44
Price-to-Earnings (P/E) Ratio -1.65
Price-to-Sales 3.90
Price-to-Book 44.19
PEG Ratio -0.69
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.95
Resistance 3 (R3) 19.07 18.61 18.67
Resistance 2 (R2) 18.61 18.17 18.55 18.57
Resistance 1 (R1) 17.92 17.90 17.69 17.80 18.48
Pivot Point 17.46 17.46 17.34 17.40 17.46
Support 1 (S1) 16.77 17.02 16.54 16.66 15.98
Support 2 (S2) 16.31 16.75 16.25 15.89
Support 3 (S3) 15.62 16.31 15.79
Support 4 (S4) 15.51